Literature DB >> 31213082

Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.

Thomas Gevaert1,2,3, Alessia Cimadamore4, Markus Eckstein5, Marina Scarpelli4, Antonio Lopez-Beltran6, Liang Cheng7, Rodolfo Montironi4.   

Abstract

Entities:  

Keywords:  PD-L1; atezolizumab; basal-type; genitourinary tumors; immunotherapy; luminal-type; lymphocytes; microbiome; urothelial carcinoma

Year:  2019        PMID： 31213082     DOI： 10.2217/fon-2019-0217

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  3 in total

Review 1.  Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.

Authors:  Alessia Cimadamore; Gaetano Aurilio; Franco Nolé; Francesco Massari; Marina Scarpelli; Matteo Santoni; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  Cells       Date:  2020-06-19       Impact factor: 6.600

Review 2.  Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.

Authors:  Antonio Lopez-Beltran; Alessia Cimadamore; Ana Blanca; Francesco Massari; Nuno Vau; Marina Scarpelli; Liang Cheng; Rodolfo Montironi
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

3.  Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.

Authors:  Veronika Weyerer; Pamela L Strissel; Reiner Strick; Danijel Sikic; Carol I Geppert; Simone Bertz; Fabienne Lange; Helge Taubert; Sven Wach; Johannes Breyer; Christian Bolenz; Philipp Erben; Bernd J Schmitz-Draeger; Bernd Wullich; Arndt Hartmann; Markus Eckstein
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.